Printer Friendly

BRADLEY PHARMACEUTICALS REPORTS 131 PERCENT INCREASE IN FIRST QUARTER SALES

 BRADLEY PHARMACEUTICALS REPORTS 131 PERCENT INCREASE
 IN FIRST QUARTER SALES
 FAIRFIELD, N.J., May 12 /PRNewswire/ -- Bradley Pharmaceuticals, Inc., (NASDAQ: BPRXA) reported today that sales for the first quarter ending March 31, 1992 rose 131 percent to $501,843 from $217,058 in a similar period in 1991. The sales increase for the first quarter was substantially due to the continued sales success of its DUADACIN cold capsule, acquired from Hoechst-Roussel Pharmaceuticals and the continuing growth of its in-line products.
 BRADLEY PHARMACEUTICALS, INC.
 Comparative First Quarter Results
 Three months ended March 31 1992 1991
 Net Sales $ 501,843 $ 217,058
 Cost of Sales 188,128 106,358
 Total 313,715 110,700
 Selling, General and
 Administrative Expense 345,105 218,369
 Loss From Operations (31,390) (107,669)
 Other Income (expense)
 Interest Income 44,944 -
 Interest Expense (15,981) (24,893)
 Total 28,963 (24,893)
 Net Loss $ (2,427)$ (132,562)
 Net (loss)
 Per Common Share $ (.00) $ (.29)
 Weighted Average Number
 Of Common Shares 2,175,000 450,000
 Bradley Pharmaceuticals, Inc. lost $2,427 for the first quarter, a significant improvement over the loss of $132,562 in the same period of a year ago. Sales responded positively to the overall advertising and other promotional programs.
 The company also reported a favorable reduction in its cost of goods over previous periods. The combination of increased sales and reduction in cost of goods is viewed by management as the first steps in creating a positive earnings picture for the company.
 In the first quarter 1992, the company completed the acquisition of NEOLOID from American Cyanamid, Lederle Laboratories division. NEOLOID is an effective cathartic laxative, and also is useful prior to Barium Enemas, as well as after the enema if another procedure requiring bowel evacuation is needed. This product is now being shipped to wholesalers, drugstores, and hospitals. Promotion to over 3,000 hospitals and 17,000 nursing homes has been implemented within the past few days.
 The company continued its international expansion with distributors contracted to represent Bradley Pharmaceuticals, Inc. in Korea, Barbados, the Dominican Republic, Jamaica, and Puerto Rico. Continuing discussions were reported by the company in its efforts to further expand in the Caribbean basin and the Pacific rim.
 Bradley Pharmaceuticals, Inc. markets ethical prescription and non-prescription pharmaceuticals in five major categories: hematinic, cough/cold, nutritional, cardiovascular, and dermatological. The company acquires non-strategic products from major pharmaceutical companies and repositions and promotes the products to a determined niche marketplace.
 -0- 5/12/92
 /CONTACT: Richard L. Audet, Chief Financial Officer of Bradley Pharmaceuticals, 201-882-1505/
 (BPRXA) CO: Bradley Pharmaceuticals, Inc. ST: New Jersey IN: MTC SU: ERN


TQ -- NY078 -- 9213 05/12/92 14:35 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 12, 1992
Words:448
Previous Article:SUTTON TILGHMAN TEAM TO HOLD POST-ELECTION PRESS CONFERENCE
Next Article:AMCARE'S NINE MONTH'S PROFITS UP 94 PERCENT
Topics:


Related Articles
BRADLEY PHARMACEUTICALS REPORTS RECORD QUARTERLY SALES AND SUCCESSFUL COMPLETION OF I.P.O. OVERALLOTMENT OFFERING
/C O R E C T I O N -- Bradley Pharmaceuticals Earnings
BRADLEY PHARMACEUTICALS REPORTS RESULTS
SYNTEX SECOND QUARTER E.P.S. OF $.54 EVEN WITH PRIOR YEAR
Bradley Pharmaceuticals Reports Strong First Quarter Sales & Earnings; Earnings Increase 38% in the Quarter.
Bradley Pharmaceuticals Announces First Quarter 2000 Results.
Bradley Pharmaceuticals Increases Guidance Based on Positive First Quarter 2001 Sales and Earnings Results.
Bradley Pharmaceuticals Reports Strong Second Quarter 2001 Results: Sales Up 45%, Profit Up 185%.
Bradley Pharmaceuticals Anticipated Third Quarter Sales and Earnings Growth Estimated to Exceed Guidance.
Bradley Pharmaceuticals Record Third Quarter Results; Sales up 42%, Income up 149%.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters